Announcement PDF Appendix 3Y Change of Director’s Interest Notice Rule 3.19A.2 Appendix 3Y Change of Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/09/01 Amended 01/01/11 Name of entity Imagion Biosystems Limited ABN 42 616 305 027 We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act. Name of Director Michael Harsh Date of last notice 6 August 2020 Part 1 - Change of director’s relevant interests in securities In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part. Direct or indirect interest Direct Nature of indirect interest (including registered holder) N/A Note: Provide details of the circumstances giving rise to the relevant interest. Date of change 28 April 2023 No. of securities held prior to change Class 1) 260,000 Ordinary Shares 2) 60,000 Listed IBXOA options (exercisable at $0.03, expiring on 28 April 2023) 3) 250,000 Unlisted Performance Options (exercisable at $0.028, vesting on 1 May 2021, expiring 1 May 2026) 4) 250,000 Unlisted Performance Options (exercisable at $0.028, vesting on 1 May 2022, expiring 1 May 2027) Listed options Number acquired Nil + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 1 Appendix 3Y Change of Director’s Interest Notice 2) 60,000 Number disposed Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation Nil 1) 260,000 Ordinary Shares 2) Nil Listed IBXOA options (exercisable at $0.03, expiring on 28 April 2023) 3) 250,000 Unlisted Performance Options (exercisable at $0.028, vesting on 1 May 2021, expiring 1 May 2026) 4) 250,000 Unlisted Performance Options (exercisable at $0.028, vesting on 1 May 2022, expiring 1 May 2027) No. of securities held after change Listed options expired Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buyback Part 2 – Change of director’s interests in contracts Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part. Detail of contract N/A Nature of interest N/A Name of registered holder (if issued securities) N/A Date of change N/A No. and class of securities to which N/A interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed Interest acquired N/A Interest disposed N/A + See chapter 19 for defined terms. Appendix 3Y Page 2 01/01/2011 Appendix 3Y Change of Director’s Interest Notice Value/Consideration N/A Note: If consideration is non-cash, provide details and an estimated valuation Interest after change N/A Part 3 – +Closed period Were the interests in the securities or contracts detailed No above traded during a +closed period where prior written clearance was required? If so, was prior written clearance provided to allow the N/A trade to proceed during this period? If prior written clearance was provided, on what date was N/A this provided? + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 3 Appendix 3Y Change of Director’s Interest Notice Rule 3.19A.2 Appendix 3Y Change of Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/09/01 Amended 01/01/11 Name of entity Imagion Biosystems Limited ABN 42 616 305 027 We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act. Name of Director David Ludvigson Date of last notice 23 November 2021 Part 1 - Change of director’s relevant interests in securities In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part. Direct or indirect interest Direct Nature of indirect interest (including registered holder) N/A Note: Provide details of the circumstances giving rise to the relevant interest. Date of change 28 April 2023 No. of securities held prior to change Class 1) 545,000 Ordinary Shares 2) 120,000 Listed IBXOA options (exercisable at $0.03, expiring on 28 April 2023) 3) 250,000 Unlisted Performance Options (exercisable at $0.028, vesting on 1 May 2021, expiring 1 May 2026) 4) 250,000 Unlisted Performance Options (exercisable at $0.028, vesting on 1 May 2022, expiring 1 May 2027) Listed options Number acquired Nil + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 1 Appendix 3Y Change of Director’s Interest Notice 2) 120,000 Number disposed Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation Nil 1) 545,000 Ordinary Shares 2) Nil Listed IBXOA options (exercisable at $0.03, expiring on 28 April 2023) 3) 250,000 Unlisted Performance Options (exercisable at $0.028, vesting on 1 May 2021, expiring 1 May 2026) 4) 250,000 Unlisted Performance Options (exercisable at $0.028, vesting on 1 May 2022, expiring 1 May 2027) No. of securities held after change Listed options expired Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buyback Part 2 – Change of director’s interests in contracts Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part. Detail of contract N/A Nature of interest N/A Name of registered holder (if issued securities) N/A Date of change N/A No. and class of securities to which N/A interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed Interest acquired N/A Interest disposed N/A + See chapter 19 for defined terms. Appendix 3Y Page 2 01/01/2011 Appendix 3Y Change of Director’s Interest Notice Value/Consideration N/A Note: If consideration is non-cash, provide details and an estimated valuation Interest after change N/A Part 3 – +Closed period Were the interests in the securities or contracts detailed No above traded during a +closed period where prior written clearance was required? If so, was prior written clearance provided to allow the N/A trade to proceed during this period? If prior written clearance was provided, on what date was N/A this provided? + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 3 Appendix 3Y Change of Director’s Interest Notice Rule 3.19A.2 Appendix 3Y Change of Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/09/01 Amended 01/01/11 Name of entity Imagion Biosystems Limited ABN 42 616 305 027 We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act. Name of Director Jovanka Naumoska Date of last notice 26 April 2023 Part 1 - Change of director’s relevant interests in securities In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part. Direct or indirect interest Direct Nature of indirect interest (including registered holder) N/A Note: Provide details of the circumstances giving rise to the relevant interest. Date of change 28 April 2023 No. of securities held prior to change Class 1) 292,500 Ordinary Shares 2) 60,000 Listed IBXOA options (exercisable at $0.03, expiring on 28 April 2023) 3) 250,000 Unlisted Performance Options (exercisable at $0.028, vesting on 1 May 2021, expiring 1 May 2026) 4) 250,000 Unlisted Performance Options (exercisable at $0.028, vesting on 1 May 2022, expiring 1 May 2027) Listed options Number acquired Nil + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 1 Appendix 3Y Change of Director’s Interest Notice 2) 60,000 Number disposed Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation Nil 1) 292,500 Ordinary Shares 2) Nil Listed IBXOA options (exercisable at $0.03, expiring on 28 April 2023) 3) 250,000 Unlisted Performance Options (exercisable at $0.028, vesting on 1 May 2021, expiring 1 May 2026) 4) 250,000 Unlisted Performance Options (exercisable at $0.028, vesting on 1 May 2022, expiring 1 May 2027) No. of securities held after change IBXOA options expired Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buyback Part 2 – Change of director’s interests in contracts Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part. Detail of contract N/A Nature of interest N/A Name of registered holder (if issued securities) N/A Date of change N/A No. and class of securities to which N/A interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed Interest acquired N/A Interest disposed N/A + See chapter 19 for defined terms. Appendix 3Y Page 2 01/01/2011 Appendix 3Y Change of Director’s Interest Notice Value/Consideration N/A Note: If consideration is non-cash, provide details and an estimated valuation Interest after change N/A Part 3 – +Closed period Were the interests in the securities or contracts detailed No above traded during a +closed period where prior written clearance was required? If so, was prior written clearance provided to allow the N/A trade to proceed during this period? If prior written clearance was provided, on what date was N/A this provided? + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 3 Appendix 3Y Change of Director’s Interest Notice Rule 3.19A.2 Appendix 3Y Change of Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/09/01 Amended 01/01/11 Name of entity Imagion Biosystems Limited ABN 42 616 305 027 We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act. Name of Director Mark Van Asten Date of last notice 26 April 2023 Part 1 - Change of director’s relevant interests in securities In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part. Direct or indirect interest Direct Nature of indirect interest (including registered holder) N/A Note: Provide details of the circumstances giving rise to the relevant interest. Date of change 28 April 2023 No. of securities held prior to change Class 1) 613,125 Ordinary Shares 2) 120,000 Listed IBXOA options (exercisable at $0.03, expiring on 28 April 2023) 3) 250,000 Unlisted Performance Options (exercisable at $0.028, vesting on 1 May 2021, expiring 1 May 2026) 4) 250,000 Unlisted Performance Options (exercisable at $0.028, vesting on 1 May 2022, expiring 1 May 2027) Listed options Number acquired Nil + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 1 Appendix 3Y Change of Director’s Interest Notice 2) 120,000 Number disposed Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation Nil 1) 613,125 Ordinary Shares 2) Nil Listed IBXOA options (exercisable at $0.03, expiring on 28 April 2023) 3) 250,000 Unlisted Performance Options (exercisable at $0.028, vesting on 1 May 2021, expiring 1 May 2026) 4) 250,000 Unlisted Performance Options (exercisable at $0.028, vesting on 1 May 2022, expiring 1 May 2027) No. of securities held after change IBXOA options expired Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buyback Part 2 – Change of director’s interests in contracts Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part. Detail of contract N/A Nature of interest N/A Name of registered holder (if issued securities) N/A Date of change N/A No. and class of securities to which N/A interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed Interest acquired N/A Interest disposed N/A + See chapter 19 for defined terms. Appendix 3Y Page 2 01/01/2011 Appendix 3Y Change of Director’s Interest Notice Value/Consideration N/A Note: If consideration is non-cash, provide details and an estimated valuation Interest after change N/A Part 3 – +Closed period Were the interests in the securities or contracts detailed No above traded during a +closed period where prior written clearance was required? If so, was prior written clearance provided to allow the N/A trade to proceed during this period? If prior written clearance was provided, on what date was N/A this provided? + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 3 Appendix 3Y Change of Director’s Interest Notice Rule 3.19A.2 Appendix 3Y Change of Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/09/01 Amended 01/01/11 Name of entity Imagion Biosystems Limited ABN 42 616 305 027 We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act. Name of Director Robert Proulx Date of last notice 23 November 2021 Part 1 - Change of director’s relevant interests in securities In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part. Direct or indirect interest Direct Nature of indirect interest (including registered holder) N/A Note: Provide details of the circumstances giving rise to the relevant interest. Date of change No. of securities held prior to change 28 April 2023 listed options 30 April 2023 performance rights 1) 6,163,250 Ordinary Shares 2) 5,000,000 Performance Rights 3) 282,000 Listed IBXOA options (exercisable at $0.03, expiring on 28 April 2023) 4) 2,000,000 Unlisted Performance Options (exercisable at $0.028, vesting on 1 May 2021, expiring 1 May 2026) 5) 2,000,000 Unlisted Performance Options (exercisable at $0.028, vesting on 1 May 2022, expiring 1 May 2027) 6) 2,000,000 Unlisted Performance Options (exercisable at $0.028, vesting on 1 May 2023, expiring 1 May 2028) + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 1 Appendix 3Y Change of Director’s Interest Notice Class Listed options and performance rights Number acquired Nil Number disposed Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation Nil 2) 5,000,000 3) 282,000 1) 6,163,250 Ordinary Shares 2) 5,000,000 Performance Rights 3) Nil Listed IBXOA options (exercisable at $0.03, expiring on 28 April 2023) 4) 2,000,000 Unlisted Performance Options (exercisable at $0.028, vesting on 1 May 2021, expiring 1 May 2026) 5) 2,000,000 Unlisted Performance Options (exercisable at $0.028, vesting on 1 May 2022, expiring 1 May 2027) 6) 2,000,000 Unlisted Performance Options (exercisable at $0.028, vesting on 1 May 2023, expiring 1 May 2028) No. of securities held after change Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buyback Listed options and performance rights expired. Part 2 – Change of director’s interests in contracts Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part. Detail of contract N/A Nature of interest N/A Name of registered holder (if issued securities) N/A Date of change N/A + See chapter 19 for defined terms. Appendix 3Y Page 2 01/01/2011 Appendix 3Y Change of Director’s Interest Notice No. and class of securities to which N/A interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed Interest acquired N/A Interest disposed N/A Value/Consideration N/A Note: If consideration is non-cash, provide details and an estimated valuation Interest after change N/A Part 3 – +Closed period Were the interests in the securities or contracts detailed No above traded during a +closed period where prior written clearance was required? If so, was prior written clearance provided to allow the N/A trade to proceed during this period? If prior written clearance was provided, on what date was N/A this provided? + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 3